Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Triglycerides Glucose Index on Angiographic Profiling of Non-Diabetic Premature Coronary Artery Disease Patients

NCT07154186 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2025-09-04
Last updated
2025-09-05

Condition(s) studied

Triglycerides Glucose IndexAngiographic ProfilingNon-DiabeticPrematureCoronary Artery Disease

Investigational drug(s) / intervention(s)

Coronary Angiographic Assessment

Coronary Angiographic Assessment: Coronary angiographic assessment will be performed for all patients.

Study summary

This study aims to evaluate the impact of the triglyceride-glucose (TyG) index on the angiographic profiling of non-diabetic patients with premature coronary artery disease (CAD).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years old. * Both sexes. * Non-diabetic patients \[no history of diabetes, hemoglobin A1C (HbA1C) \< 6.5%, fasting glucose \< 126 mg/dL\]. * Confirmed diagnosis of coronary artery disease (CAD) by coronary angiography. Exclusion Criteria: * Known diabetes mellitus (type 1 or type 2). * Previous history of coronary revascularization. * Severe hepatic or renal dysfunction \[alanine transaminase (ALT)/aspartate aminotransferase (AST) ≥ 5× upper limit of normal (ULN), estimated glomerular filtration rate (eGFR)\< 30 mL/min/1.73 m²\]. * Malignant disease, autoimmune disease, or systemic inflammatory disorders. * Current use of triglyceride-lowering medications.

Primary outcome measure(s)

  • Incidence of ischemia- driven revascularization — 6 months post-procedure
    Incidence of ischemia- driven revascularization will be recorded.

Trial sites (1)

FacilityCityRegionStatus
Sohag University Sohag Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07154186 on ClinicalTrials.gov ↗ ← All trials in Egypt